Commission targets AstraZeneca, Nycomed others for suspected antitrust violations
This article was originally published in SRA
The European Commission has carried out new, unannounced raids at the premises of some pharmaceutical companies in a number of EU member states on the suspicion that the companies may have acted individually or jointly to delay generic entry for a particular medicine1,2.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.